Professional
Added to YB: 2026-06-05
Pitch date: 2026-06-03
STVN [neutral]
Stevanato Group S.p.A.
-0.11%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Market Cap
$4.4B
Pitch Price
$18.53
Price Target
N/A
Dividend
0.34%
EV/EBITDA
15.93
P/E
31.30
EV/Sales
3.90
Sector
Life Sciences Tools and Services
Category
growth
Pernas Research More Research Needed On: Stevanato Group
STVN (needs more research): Drug containment/delivery oligopoly (syringes, cartridges, vials); mkt cap $5.2B, $18.80, 16.3x EV/EBITDA. Mkt fears GLP-1 pricing/oral shift, but GLP-1s only 21-22% Q1 rev; broad biologics demand, cartridges booked thru 2026. Q1 rev +10%, HVS 47%. Want cheaper entry; evaluating mix/margins.
Read full article (1 min)